GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill Impairment Testing and Charges

Under ASC Topic 350, Intangibles - Goodwill and Other, goodwill and intangible assets determined to have indefinite useful lives are not amortized. Instead these assets are evaluated for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. Our reporting units for purposes of assessing goodwill impairment are organized primarily based on operating segments and geography and include: (a) North America Plasma, (b) North America Blood Center, (c) North America Hospital, (d) EMEA, (e) Asia-Pacific and (f) Japan. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit.

In fiscal 2017, we early adopted ASC Update No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment. Under this amendment, entities perform their goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. We utilized a discounted cash flow approach in order to value our reporting units for the test, which required that we forecast future cash flows of the reporting units and discount the cash flow stream based upon a weighted average cost of capital that was derived, in part, from comparable companies within similar industries. The discounted cash flow calculations also included a terminal value calculation that was based upon an expected long-term growth rate for the applicable reporting unit. We believe that our procedures for estimating discounted future cash flows, including the terminal valuation, were reasonable and consistent with market conditions at the time of estimation. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test.

The results of the goodwill impairment test performed in the fourth quarter of fiscal 2018 indicated that the estimated fair value of all of our reporting units exceeded their respective carrying values. There were no reporting units at risk of impairment as of the fiscal 2018 annual test date.

During fiscal 2017, we recorded a goodwill impairment charge of $57.0 million, which represented the entire goodwill balance associated with the North America Blood Center reporting unit. There were no other reporting units at risk of impairment as of the fiscal 2017 annual test date. During fiscal 2016, we recorded a goodwill impairment charge of $66.3 million associated with the EMEA reporting unit. At the time the impairment assessment was performed, this represented the entire goodwill balance of this reporting unit. During fiscal 2017, management reorganized its operating segments such that certain components of the All Other operating segment became components of the EMEA operating segment. As a result, we transferred $20.5 million of goodwill to the EMEA operating segment, which represented the portion of the goodwill associated with these components.

The changes in the carrying amount of goodwill by operating segment for fiscal 2018 and 2017 are as follows:



(In thousands)	Japan			EMEA			North America Plasma		All Other			Total
Carrying amount as of April 2, 2016	$	24,883		$	—		$	26,415	$	216,542		$	267,840
Impairment charge	—			—			—		(56,989		)	(56,989		)
Transfer of goodwill between segments	—			20,545			—		(20,545		)	—
Currency translation	(3		)	(2		)	—		(5		)	(10		)
Carrying amount as of April 1, 2017	$	24,880		$	20,543		$	26,415	$	139,003		$	210,841
Currency translation	162			134			—		258			554
Carrying amount as of March 31, 2018	$	25,042		$	20,677		$	26,415	$	139,261		$	211,395

The gross carrying amount of intangible assets and the related accumulated amortization as of March 31, 2018 and April 1, 2017 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net
As of March 31, 2018
Amortizable:
Patents	$	9,301	$	8,262	$	1,039
Capitalized software	54,095		27,117		26,978
Other developed technology	117,959		80,622		37,337
Customer contracts and related relationships	197,266		127,338		69,928
Trade names	7,178		5,939		1,239
Total	$	385,799	$	249,278	$	136,521
Non-amortizable:
In-process software development	$	17,717
In-process patents	2,351
Total	$	20,068



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net
As of April 1, 2017
Amortizable:
Patents	$	9,183	$	8,043	$	1,140
Capitalized software	49,948		21,563		28,385
Other developed technology	117,712		72,594		45,118
Customer contracts and related relationships	194,876		108,073		86,803
Trade names	7,017		5,499		1,518
Total	$	378,736	$	215,772	$	162,964
Non-amortizable:
In-process software development	$	12,743
In-process patents	1,833
Total	$	14,576

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are 5 to 18 years. The changes to the net carrying value of our intangible assets from April 1, 2017 to March 31, 2018 reflect the impact of amortization expense, partially offset by the investment in capitalized software.

Aggregate amortization expense for amortized intangible assets for fiscal 2018, 2017 and 2016 was $31.9 million, $37.2 million and $59.3 million, respectively. During fiscal 2017 and 2016, we impaired $4.8 million and $25.8 million of intangible assets, respectively. Amortization expense for fiscal 2017 and 2016 included $4.0 million and $25.4 million, respectively, of amortization expense resulting from these intangible asset impairments. There were no intangible asset impairments during fiscal 2018.

Future annual amortization expense on intangible assets is estimated to be as follows:



(In thousands)
Fiscal 2019	$	30,731
Fiscal 2020	$	29,076
Fiscal 2021	$	26,898
Fiscal 2022	$	24,941
Fiscal 2023	$	10,714

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details